DEFA14A: Novartis to Acquire Avidity Biosciences for $12B, Cardiology Spun Off

Novartis AG will acquire Avidity Biosciences for $72.00 per share in cash, valuing the company at $12.0 billion, while Avidity's early-stage cardiology programs will be spun off into a new publicly traded entity, SpinCo.

Summary

• Novartis AG will acquire Avidity Biosciences, Inc. for $72.00 per share in cash, representing a total equity value of approximately $12.0 billion on a fully diluted basis.
• The acquisition price represents a premium of approximately 46% over Avidity's closing share price of $49.15 on October 24, 2025, and approximately 62% over its 30-day volume weighted average price of $44.42.
• Prior to the acquisition, Avidity will spin off its early-stage precision cardiology programs and certain collaboration agreements into a new, independent publicly traded company, SpinCo (Bryce Therapeutics, Inc.).
• Avidity stockholders will receive one share of SpinCo common stock for every ten shares of Avidity common stock they hold, or a pro rata cash distribution if certain SpinCo assets or SpinCo itself is sold to a third party.
• SpinCo will be capitalized with $270 million in cash and is expected to begin trading as a new public company following the spin-off.
• The transaction is subject to customary closing conditions, including the completion of the SpinCo separation, regulatory approvals (HSR Act, antitrust laws), and approval by Avidity's stockholders.
• The merger and spin-off are expected to be taxable events for Avidity's stockholders.
• The acquisition will grant Novartis access to Avidity's neuroscience pipeline, including late-stage clinical development programs for Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD), as well as its RNA-targeting delivery platform.
• SpinCo's pipeline will focus on early-stage precision cardiology programs, including AOC 1086 and AOC 1072, targeting rare genetic cardiomyopathies, and will retain rights to develop Avidity's proprietary platform for cardiology applications.

Sentiment

Score: 9

Explanation: The filing announces a significant acquisition at a substantial premium for Avidity shareholders, coupled with a strategic spin-off of cardiology assets, which provides clear value and future potential. While there are customary risks and complexities, the immediate financial benefit to shareholders is very strong.

Positives

• Avidity stockholders will receive a significant cash premium of approximately 46% over the prior day's closing price and 62% over the 30-day volume weighted average price.
• The transaction provides a clear valuation for Avidity's neuroscience assets and RNA-targeting delivery platform, which will be integrated into Novartis.
• The spin-off creates a new, independent publicly traded company (SpinCo) focused on early-stage precision cardiology programs, allowing for specialized development and potential future value creation.
• SpinCo will be well-capitalized with $270 million in cash, providing resources for its initial operations and development efforts.
• The strategic separation allows both the acquired entity (Avidity's neuroscience programs) and SpinCo (cardiology programs) to pursue their respective therapeutic areas with focused management and resources.

Negatives

• The merger and spin-off are expected to be taxable events for Avidity's stockholders.
• Avidity is subject to a $450 million termination fee payable to Novartis under certain circumstances, such as accepting a superior proposal or a change in recommendation.
• The transaction involves complex separation and regulatory processes, which could lead to unforeseen costs or delays.
• Stockholders will need to manage two separate investments (cash from acquisition and SpinCo shares) post-transaction, which may introduce additional administrative and market risks for SpinCo.

Risks

• The timing of the satisfaction of customary closing conditions, including regulatory approvals and Avidity's stockholder approval, may not occur on the expected timetable or at all.
• Risks and costs related to the implementation of the separation of SpinCo, including the ability to complete the separation in the anticipated timeframe, or at all, and any changes to the configuration of the businesses included in the separation if implemented.
• The potential sale of certain of SpinCo's assets pursuant to a third-party right of first negotiation.
• The risk that competing offers or acquisition proposals will be made for Avidity.
• The effects of disruption from the transactions and the impact of the announcement and pendency of the transactions on Novartis's and/or Avidity's businesses, including their relationships with employees, business partners, or governmental entities.
• The risk that the transactions may be more expensive to complete than anticipated.
• The risk that stockholder litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.
• A diversion of management's attention from ongoing business operations and opportunities as a result of the transactions or otherwise.
• Uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data.
• Regulatory actions or delays or government regulation generally.
• No guarantee that Avidity's investigational products will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time.
• No guarantee that Avidity's approach to the discovery and development of product candidates based on its AOC platform will produce any products of commercial value.
• No guarantee that the expected benefits or synergies from the transactions will be achieved in the expected timeframe, or at all.

Future Outlook

The parties expect the merger, spin-off, and other contemplated transactions to close in the first half of 2026, subject to the satisfaction of customary closing conditions, including regulatory approvals and stockholder approval. There is no guarantee that investigational products will be approved or that expected benefits and synergies will be achieved. SpinCo is expected to begin trading as a new public company following the spin-off, focusing on its early-stage precision cardiology programs.

Management Comments

• Sarah Boyce, President and CEO of Avidity, stated that the transaction with Novartis maximizes value for investors and will support the global expansion of Avidity's neuroscience pipeline, expressing pride in the company's achievements and gratitude to the team and patient communities.
• Kathleen Gallagher, currently Chief Program Officer at Avidity and designated CEO of SpinCo, highlighted the tremendous impact targeted delivery of RNA therapeutics to muscle can have for rare diseases and expressed excitement to lead the team building on the AOC platform for cardiovascular diseases.

Industry Context

This announcement reflects a broader trend in the biopharmaceutical industry where larger pharmaceutical companies acquire innovative biotech firms to bolster their pipelines, particularly in high-growth therapeutic areas like RNA therapeutics and rare diseases. The simultaneous spin-off of early-stage assets allows the acquiring company to focus on more advanced programs while enabling the spun-off entity to attract specialized investment for its distinct, earlier-stage development focus, optimizing value for both sets of assets.

Management Changes

Corporate Governance

Legal Proceedings

• The risk of stockholder litigation in connection with the transactions is noted, which may result in significant costs of defense, indemnification, and liability.

Related Party Transactions

• The separation of Avidity's early-stage precision cardiology programs into SpinCo involves the transfer of assets and liabilities between Avidity and SpinCo, governed by a Separation and Distribution Agreement and a License Agreement. This creates new related party relationships and agreements between the two entities prior to SpinCo becoming fully independent.

Stakeholder Impact

• Shareholders: Will receive a significant cash premium for their Avidity shares and shares in the new SpinCo, or cash proceeds from a potential sale of SpinCo assets.
• Employees: Management changes are noted for SpinCo, with Kathleen Gallagher becoming CEO and Sarah Boyce becoming Chair. The transaction may cause disruption and impact relationships with employees.
• Business Partners: The announcement and pendency of the transactions could impact relationships with business partners.
• Customers: Potential impact on customers is not explicitly detailed but could arise from changes in company structure or product focus.
• Regulatory Authorities: The transaction requires regulatory approvals, and ongoing R&D is subject to regulatory actions and delays.

Next Steps

• Avidity will prepare and file a preliminary proxy statement for a special meeting of stockholders to approve the Merger Agreement and Separation and Distribution Agreement no later than 30 days after October 25, 2025.
• Avidity will use reasonable best efforts to submit or file the Spin-Off Registration Statement within 60 days after October 25, 2025, and no later than 90 days after October 25, 2025.
• Avidity will hold a special meeting of stockholders to obtain the Requisite Company Vote for the adoption of the Merger Agreement and Separation and Distribution Agreement.
• The companies will work to obtain necessary regulatory approvals, including under the HSR Act and other antitrust laws.
• SpinCo is expected to begin trading as a new public company following the spin-off, with a listing application to be filed with Nasdaq.

Key Dates

Recommendation

The acquisition of Avidity Biosciences by Novartis AG at $72.00 per share represents a substantial premium of 46% over the previous day's closing price and 62% over the 30-day VWAP. This offers a compelling and immediate return for current shareholders. The strategic spin-off of the cardiology programs into a new, well-capitalized public entity (SpinCo) also provides additional, albeit more speculative, future value. Given the high premium and the clear path to monetization for Avidity shareholders, a strong buy recommendation is warranted to capture the acquisition premium.

Keywords

Avidity Biosciences, Novartis AG, Acquisition, Merger, Spin-Off, RNA Therapeutics, Antibody Oligonucleotide Conjugates, AOCs, Neuroscience, Cardiology, Duchenne Muscular Dystrophy, DM1, FSHD, Rare Genetic Cardiomyopathies, Biopharmaceutical, Clinical Development